在异质HR表达模式中,HER2-低和HER2-零乳腺癌生存结果的差异:现实研究
Yi Zeng1, Pengfei Qian1, Guanhong Li1
1Department of Breast Surgery, The Affiliated Huizhou Hospital, Guangzhou Medical University, No.1 Xuebei Road, Huizhou, Guangdong, 516000, China.
World journal of surgical oncology
|September 4, 2025
概括
低HER2的乳腺癌患者的生存率通常比HER2零的患者更好. 激素受体表达进一步细化这些结果,指导 HER2 阴性乳腺癌的个性化治疗.
科学领域:
- 癌症学
- 乳腺癌研究
- 分子病理学
背景情况:
- HER2 阴性乳腺癌被分为 HER2 低和 HER2 零.
- 人们越来越认识到HER2低的状态是影响治疗反应和预后的重要因素.
- 组合激素受体 (HR) 表达模式对HER2阴性亚型的影响仍未得到充分研究.
研究的目的:
- 研究不同雌激素受体 (ER) 和孕激素受体 (PR) 表达模式在HER2阴性乳腺癌亚型中的预后意义.
- 为了比较不同HR表达型的HER2-低和HER2-零乳腺癌患者的生存结果.
- 确定HER2低状态是否是HER2阴性乳腺癌的独立预后因素.
主要方法:
- 在2010年至2023年期间治疗的648名HER2阴性乳腺癌患者的回顾性分析.
- 根据ER,PR和HER2的表达分为六个分层 (HER2-低与HER2-零).
- 无病生存期 (DFS) 和整体生存期 (OS) 的比较,以及临床和病理特征.
主要成果:
- 与HER2- 0患者相比,HER2- 2低患者的ER阳性患病率更高.
- 低HER2乳腺癌中的ER+/ PR+亚组表现出有利的特征:较低的N阶段,较低的组织学等级,较低的Ki-67%,以及较高的病理完整反应率 (pCR).
- 低HER2状态与整体生存结果的改善有关,并被确定为独立的预后因素. 与单个HR+/HER2低患者相比,ER+/PR+/HER2低患者的寿命显著更长.
结论:
- 与HER2- 0乳腺癌相比,低HER2- 2乳腺癌与更高的生存结果有关.
- 在不同激素受体表达型的低HER2乳腺癌中存在不同的生存模式.
- 这些发现强调了在 HER2 阴性乳腺癌中考虑 HER2 和 HR 状态对于量身定制治疗策略的重要性.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
279
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
279
01:21Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
01:12Hazard Ratio
240
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
240